Clinical Trial Update: Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 therapeutic equivalence study comparing Hanmi's HCP0910 250/50 mcg inhaler to GlaxoSmithKline's S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• HCP0910 250/50 mcg
• Seretide 250 Diskus (fluticasone propionate/salmeterol)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Asthma | Phase 1 | Status: COMPLETED